Gilead Sciences annual cash and equivalents
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Cash & Equivalents Growth & History (GILD)
Gilead Sciences's cash and equivalents was $7.56B for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.56B | −$2.43B | −24.29% |
| 2024 | 2024-12-31 | $9.99B | $3.91B | +64.19% |
| 2023 | 2023-12-31 | $6.08B | $673.0M | +12.44% |
| 2022 | 2022-12-31 | $5.41B | $74.0M | +1.39% |
| 2021 | 2021-12-31 | $5.34B | −$659.0M | −10.99% |
| 2020 | 2020-12-31 | $6.00B | −$5.63B | −48.44% |
| 2019 | 2019-12-31 | $11.63B | −$6.31B | −35.17% |
| 2018 | 2018-12-31 | $17.94B | $10.35B | +136.43% |
| 2017 | 2017-12-31 | $7.59B | −$641.0M | −7.79% |
| 2016 | 2016-12-31 | $8.23B | −$4.62B | −35.97% |
| 2015 | 2015-12-31 | $12.85B | $2.82B | +28.16% |
| 2014 | 2014-12-31 | $10.03B | $7.91B | +374.54% |
| 2013 | 2013-12-31 | $2.11B | $309.0M | +17.13% |
| 2012 | 2012-12-31 | $1.80B | −$8.08B | −81.75% |
| 2011 | 2011-12-31 | $9.88B | $8.98B | +988.69% |
| 2010 | 2010-12-31 | $907.9M | −$365.1M | −28.68% |
| 2009 | 2009-12-31 | $1.27B | −$186.3M | −12.77% |
| 2008 | 2008-12-31 | $1.46B | $491.2M | +50.74% |
| 2007 | 2007-12-31 | $968.1M | — | — |
Gilead Sciences quarterly cash and equivalents
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.18B | −$1.97B | −38.20% |
| Q1 2026 | 2026-03-31 | $7.63B | −$298.0M | −3.76% |
| Q4 2025 | 2025-12-31 | $7.56B | −$2.43B | −24.29% |
| Q3 2025 | 2025-09-30 | $7.33B | $2.29B | +45.52% |
| Q2 2025 | 2025-06-30 | $5.14B | $2.37B | +85.57% |
| Q1 2025 | 2025-03-31 | $7.93B | $3.21B | +67.99% |
| Q4 2024 | 2024-12-31 | $9.99B | $3.91B | +64.19% |
| Q3 2024 | 2024-09-30 | $5.04B | −$668.0M | −11.71% |
| Q2 2024 | 2024-06-30 | $2.77B | −$2.93B | −51.40% |
| Q1 2024 | 2024-03-31 | $4.72B | −$218.0M | −4.42% |
| Q4 2023 | 2023-12-31 | $6.08B | $673.0M | +12.44% |
| Q3 2023 | 2023-09-30 | $5.71B | $1.01B | +21.41% |
| Q2 2023 | 2023-06-30 | $5.70B | $965.0M | +20.36% |
| Q1 2023 | 2023-03-31 | $4.94B | $640.0M | +14.90% |
| Q4 2022 | 2022-12-31 | $5.41B | $74.0M | +1.39% |
| Q3 2022 | 2022-09-30 | $4.70B | $337.0M | +7.73% |
| Q2 2022 | 2022-06-30 | $4.74B | −$154.0M | −3.15% |
| Q1 2022 | 2022-03-31 | $4.30B | $231.0M | +5.68% |
| Q4 2021 | 2021-12-31 | $5.34B | −$659.0M | −10.99% |
| Q3 2021 | 2021-09-30 | $4.36B | −$8.52B | −66.15% |
| Q2 2021 | 2021-06-30 | $4.89B | −$1.85B | −27.47% |
| Q1 2021 | 2021-03-31 | $4.07B | −$5.99B | −59.56% |
| Q4 2020 | 2020-12-31 | $6.00B | −$5.63B | −48.44% |
| Q3 2020 | 2020-09-30 | $12.89B | $3.41B | +36.01% |
| Q2 2020 | 2020-06-30 | $6.75B | −$4.49B | −39.98% |
| Q1 2020 | 2020-03-31 | $10.05B | −$6.88B | −40.62% |
| Q4 2019 | 2019-12-31 | $11.63B | −$6.31B | −35.17% |
| Q3 2019 | 2019-09-30 | $9.47B | −$5.09B | −34.97% |
| Q2 2019 | 2019-06-30 | $11.24B | −$1.99B | −15.07% |
| Q1 2019 | 2019-03-31 | $16.93B | $9.28B | +121.47% |
| Q4 2018 | 2018-12-31 | $17.94B | $10.35B | +136.43% |
| Q3 2018 | 2018-09-30 | $14.57B | $3.06B | +26.60% |
| Q2 2018 | 2018-06-30 | $13.23B | $4.52B | +51.91% |
| Q1 2018 | 2018-03-31 | $7.64B | −$2.64B | −25.69% |
| Q4 2017 | 2017-12-31 | $7.59B | −$641.0M | −7.79% |
| Q3 2017 | 2017-09-30 | $11.51B | $1.70B | +17.32% |
| Q2 2017 | 2017-06-30 | $8.71B | $2.23B | +34.34% |
| Q1 2017 | 2017-03-31 | $10.29B | $3.97B | +62.87% |
| Q4 2016 | 2016-12-31 | $8.23B | −$4.62B | −35.97% |
| Q3 2016 | 2016-09-30 | $9.81B | −$4.16B | −29.76% |
| Q2 2016 | 2016-06-30 | $6.49B | −$932.0M | −12.57% |
| Q1 2016 | 2016-03-31 | $6.32B | −$4.32B | −40.62% |
| Q4 2015 | 2015-12-31 | $12.85B | $2.82B | +28.16% |
| Q3 2015 | 2015-09-30 | $13.96B | $7.76B | +124.92% |
| Q2 2015 | 2015-06-30 | $7.42B | −$1.31B | −15.05% |
| Q1 2015 | 2015-03-31 | $10.63B | $4.23B | +66.07% |
| Q4 2014 | 2014-12-31 | $10.03B | $7.91B | +374.54% |
| Q3 2014 | 2014-09-30 | $6.21B | $4.20B | +208.79% |
| Q2 2014 | 2014-06-30 | $8.73B | $6.53B | +296.47% |
| Q1 2014 | 2014-03-31 | $6.40B | $4.54B | +243.57% |
| Q4 2013 | 2013-12-31 | $2.11B | $309.0M | +17.13% |
| Q3 2013 | 2013-09-30 | $2.01B | $460.0M | +29.67% |
| Q2 2013 | 2013-06-30 | $2.20B | $576.7M | +35.48% |
| Q1 2013 | 2013-03-31 | $1.86B | $412.0M | +28.38% |
| Q4 2012 | 2012-12-31 | $1.80B | −$8.08B | −81.75% |
| Q3 2012 | 2012-09-30 | $1.55B | $641.4M | +70.53% |
| Q2 2012 | 2012-06-30 | $1.63B | $719.7M | +79.46% |
| Q1 2012 | 2012-03-31 | $1.45B | −$384.0M | −20.92% |
| Q4 2011 | 2011-12-31 | $9.88B | $8.98B | +988.69% |
| Q3 2011 | 2011-09-30 | $909.4M | −$113.6M | −11.11% |
| Q2 2011 | 2011-06-30 | $905.8M | — | — |
| Q1 2011 | 2011-03-31 | $1.84B | $899.1M | +95.97% |
| Q4 2010 | 2010-12-31 | $907.9M | −$365.1M | −28.68% |
| Q3 2010 | 2010-09-30 | $1.02B | −$1.6M | −0.16% |
| Q1 2010 | 2010-03-31 | $936.9M | — | — |
| Q4 2009 | 2009-12-31 | $1.27B | −$186.3M | −12.77% |
| Q3 2009 | 2009-09-30 | $1.02B | — | — |
| Q2 2009 | 2009-06-30 | $1.04B | — | — |
| Q4 2008 | 2008-12-31 | $1.46B | — | — |
Gilead Sciences cash and equivalents trends
Over the last five fiscal years, Gilead Sciences's cash and equivalents increased from $6.00B to $7.56B, a change of $1.57B. The latest reported quarter, Q2 2026, shows $3.18B.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
